We determinedthe frequenciesof genetic apolipoproteinE isoforms in 570 survivorsof myocardial infarction,all with demonstrable coronary heart disease, as comparedwith624 healthy persons. In controls, E-4/E-3 heterozygositywas associated with total cholesterolconcentrationsof 1985 (SD 364) mg/L and low-density Iipoprotein (LDL)-cholesterol concentrations of 1306 (SD 332) mg/L. Significantly lower values, 1811 (SD 312) mg/L and 1121 (SD 274) mg/L, respectively, were observedforE-3/E-2 heterozygous persons. In survivorsof mocardial infarction, the respectivevalueswere significantly higherthan in controls,differingbetween E-4/E-3 and E-3/E-2 heterozygous patients by 233 and 220 mg/L, respectively.Moreover, E-4/E-3 heterozygositywas accompanied by earlier age of myocardlal infarction (48.8 ± 7.4 years) as comparedwith E-3/E-2 heterozygosity(53.4 ± 6.9 years) and E-3/E-3 homozygosity(51.2 ± 7.7 years). Evidently,apolipoproteinE polymorphismcan contribute to total and LDL-cholesterol concentrationsin serum,therebyaffecting riskof coronaryheart disease and myocardialinfarction.
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Apolipoprotein E (ape E) is part of all lipoprotein classes-chylomicrons
and very-low-(VLDL), low-(LDL), and high-density lipoproteins (HDL)-and exists in three major isoforms (ape E-2, ape E-3, ape E-4), which can be separated by isoelectric focusing in polyacrylamide gels and then made visible. Synthesized under the control of independent allelea at a single gene locus, ape E is subject to pesttranslational modifications (1) (2) (3) (4) . The frequencies of the genotypes in the European and North American population are very similar-0.8% ape E-2/2; 62.7% ape E-313; 2.3% ape E-414; 11.0% ape E-3/2; 3.0% ape E-4/2; 20.2% ape E-4/3 (5) .
Other known isoforms of ape E-apo E-1 (6), ape E2* (7) , ape E2** (8), ape E-2 (Bethesda) (9), ape E3* (10), ape E-3(1) (11), ape E-5 (12), and ape E-Suita (13)-are very rare.
Though several tests of ape E phenotypes and lipid status in patients suffering from coronary artery disease (CAD) have shown a complex relationship between ape E genes and lipoprotein concentrations, no reliable information about the relations of genetic ape E pelymnorphism and CAD could be obtained (14) (15) (16) (17) (18) (19) (20) (21) or left coronary arteries, the circumflex branch, or the anterior descending branch showed stenoses of more than 50%, the patient was classified as "CAD+fMI+."
Materials and Methods
Patients and Controls
I8olation of apo VLDL. One milliliter of serum (if triglycerides exceeded 1.00 g/L) or 2 mL (if triglycerides were <1.00 g/L) was centrifuged in a type 25 rotor (Beckman Instruments, Palo Alto, CA) for 24 h (4#{176}C, 25 000 rpm). The top layer, about 300 ML, was aspirated and replaced with 100 MLof a mixture containing, per liter, 9 g of NaC1 and 0.2 g of NaN3. The mixture was again ultracentrifliged, under the same conditions. If phenotyping could not be started at the same day, the washed VLDL samples were stored at -20 #{176}C. The samples were mixed with 100 mL of a 9 g/L solution of NaC1 and then delipidated at -20 #{176}C with ether/ ethanol (1/3 by vol) and pure diethyl ether.
Polyacrylamide gel isoelectric focusing. The apolipoproteins were dissolved in 50 mL of a pH 8.2 buffer containing, per liter, 10 mmol of Tris HC1, 15 g of sodium decyl sulfate, 20 g of ampholytes (pH [3] [4] [5] [6] [7] , 360 g of purified urea, 100 g of the ape E phenotypes were tested by one-way analysis of variance. The significance level was set at 0.05.
Results
The prevalence of the genetic ape E phenotypes was not significantly different between CAD +/MI+ patients and controls (Table 1) .
However, the alleles #{128}2 and #{128}4 had a major impact on total cholesterol and LDL cholesterol concentrations in both controls and CAD +/MI+ patients ( Figure 1 and Table 2 ).
In controls, total cholesterol concentrations in serum were 170 mg/L higher in E-4/E-3 heterozygotes (1985 ± 364 mg/ (Figure 1, Table 2 ). Serum HDL-cholesterol and triglyceride concentrations did not vary significantly by the various ape E phenotypes in controls and in CAD+IMI+ patients.
The reported ages at which myocardial infarction had occurred and the ages at which coronary angiography was performed'differed between E-4/E-3 and E-31E-2 hetersygous CAD+/M1+ patients by 4.6 years (p <0.01), and 4.1 years (p <0.01), respectively.
Significant differences were found, too, in the prevalence of ape E isoforms in patients with early (<50 years) and late ('50 years) infarction (Table 3) . Only 23.7% of the E-3/E-2 heterozygous persons suffering from myocardial infarction were younger than 50 years, 76.3% were older. In E-4/E-3 heterozygous patients this age dependency was reversed: 60% suffered from infarction before reaching 50 years of age and only 40% later.
Owing to the low prevalence of E-4/E-4 homozygosity and E-2/E-2 homozygosity in controls and CAD +IMI+ patients, we could not obtain meaningful data concerning differences in lipid status and manifestation of CAD in these subjects.
Discussion
As demonstrated in our study, the genetic polymorphism accordance with our previous studies of CAD patients, in which we demonstrated that the #{128}2 allele was more frequent in CAD-patients than in CAD+ patients (17) . These -570 former studies were done in patients who, at the time of coronary angiography, had not had a myocardial infarction.
n 624 However, our current data differ from observations of Utermann et al. (19) , who found a lower frequency of the apo E4 isoform in MI patients than in unaffected controls. The origin of this difference may possibly relate to the heterogeneity of MI survivors because, as observed here, only part of those patients are affected by advanced coronary atherosclerosis. Our results concerning LDL-cholesterol concentrations agree with the data of Robertson and Cununing (15) , who found lower concentrations of LDL-cholesterol in serum from healthy E-3/E-2 heterozygous men than in that from E-3/E-3 homozygotes.
Interestingly, in both controls and CAD+JMI+ patients the average differences in LDL cholesterol concentrations between E-4/E-3 heterozygotes and E-31E. aCompanson between apolipoprotein phenotypes E-4/E-3 and E-3/E-2. n.s., not significant.
Age, yr
<50
,5o Figure  1 ) cannot be explained by ape E polymorphism alone. Rather, additional genetic factors (e.g., polymorphism of ape B or LDL receptors) or environmental influences affecting the expression of LDL receptors, or both, must account for the observed high concentrations of LDL cholesterol in CAD+/MI+ patients. The influence of ape E polymorphism on the manifestation of CAD is probably a consequence of the significant differences in LDL cholesterol concentrations associated with the various ape E phenotypes.
At present, the precise metabolic effect of the various ape E-alleles on LDL cholesterol concentrations is poorly understood. Because expression of hepatic ape B,E receptors exerts major influence on LDL cholesterol concentrations in serum, one may speculate that partial downregulation of the receptors occurs in the presence of ape E-4-containing lipoproteins and partial upregulation in the presence of ape E-2-containing lipoproteins.
In this context we note that ape E-2 and ape E-3 both form stable complexes with ape All (ape E-A-il complex) (27) ; because of its lack of cysteine, ape E-4 cannot form such complexes (28) . This difference in the primary structure of ape E isoforms might cause a relative enrichment of ape E-2 and ape E-3 in HDL (as ape E-A-ll complexes) and a relative enrichment of E4 in triglyceriderich lipoproteins. Given the short turnover time of triglyceride-rich lipeproteins and the high affinity binding of ape E-4-and ape E-3-containing lipeproteins to ape E receptors (chylomicron remnants) and to ape B,E receptors (intermediate-density lipeproteins), the increased influx of cholesterol into the liver via these lipeproteins might lead to a downregulation of the ape B,E receptors. The prolonged half We thank Miss Gabriele Klapdor and Miss Anne Kruse for their excellent technical assistance.
